SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Idera Pharmaceuticals, Inc. Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients With Psoriasis
Your Message